Sarepta Elevidys FDA Scrutiny - Search News

Order byBest matchMost fresh

News

Sarepta Therapeutics, FDA and Elevidys

· 1d · on MSN

FDA probes death of patient on Sarepta's Elevidys, partner Roche says death unrelated to therapy

The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' muscular disorder gene therapy Elevidys.

Continue reading

Fierce Pharma · 5d

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market

· 19h · on MSN

What’s behind Sarepta’s gene therapy deaths?

4don MSN

Sarepta Therapeutics laying off dozens in Ohio, won't comply with FDA request to halt therapy

After the FDA request, Cambridge, Massachusetts-based Sarepta said in a statement that it will continue to ship the therapy ...

GEN - Genetic Engineering and Biotechnology News1d

Sarepta Under Scrutiny, AstraZeneca’s Big Bet, and AI vs. IDRs

This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy targets.

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results